ATE259231T1 - Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung - Google Patents

Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung

Info

Publication number
ATE259231T1
ATE259231T1 AT00926483T AT00926483T ATE259231T1 AT E259231 T1 ATE259231 T1 AT E259231T1 AT 00926483 T AT00926483 T AT 00926483T AT 00926483 T AT00926483 T AT 00926483T AT E259231 T1 ATE259231 T1 AT E259231T1
Authority
AT
Austria
Prior art keywords
liposome compositions
improved active
active retention
liposomes
fluoroquinolone
Prior art date
Application number
AT00926483T
Other languages
English (en)
Inventor
Luke S S Guo
Radwan Kiwan
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE259231T1 publication Critical patent/ATE259231T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT00926483T 1999-04-29 2000-04-28 Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung ATE259231T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13155399P 1999-04-29 1999-04-29
PCT/US2000/011625 WO2000066126A2 (en) 1999-04-29 2000-04-28 Liposome compositions for improved drug retention

Publications (1)

Publication Number Publication Date
ATE259231T1 true ATE259231T1 (de) 2004-02-15

Family

ID=22449950

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00926483T ATE259231T1 (de) 1999-04-29 2000-04-28 Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung

Country Status (17)

Country Link
EP (1) EP1176962B1 (de)
JP (1) JP2002543134A (de)
KR (1) KR100766753B1 (de)
CN (1) CN1172670C (de)
AT (1) ATE259231T1 (de)
AU (1) AU767474B2 (de)
CA (1) CA2371483A1 (de)
DE (1) DE60008234T2 (de)
DK (1) DK1176962T3 (de)
ES (1) ES2214269T3 (de)
HK (1) HK1044122B (de)
HU (1) HUP0201644A3 (de)
IL (2) IL146113A0 (de)
MX (1) MXPA01010977A (de)
NO (1) NO320629B1 (de)
WO (1) WO2000066126A2 (de)
ZA (1) ZA200108907B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
EP1429726A2 (de) * 2001-09-06 2004-06-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Verfahren zur herstellung von liposom-formulierungen mit vordefiniertem freisetzungsprofil
UA86063C2 (ru) * 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
EP1784164A4 (de) * 2004-09-03 2008-07-09 Piedmont Pharmaceuticals Llc Verfahren zur transmembranbehandlung und vorbeugung von otitis media
EP1932517A3 (de) * 2006-12-11 2008-07-16 Universiteit Utrecht Holding B.V. Liposomen beinhaltend Polyphenolderivaten und deren Verfahren zur Nachbeladung
JP5351076B2 (ja) * 2010-02-26 2013-11-27 杏林製薬株式会社 オンライン固相抽出による生体試料液中薬剤成分の定量方法
CN102309448B (zh) * 2010-06-29 2014-07-09 中国人民解放军军事医学科学院毒物药物研究所 一种肺部给药的环丙沙星药用组合物及其制备方法
JP5848511B2 (ja) * 2011-03-29 2016-01-27 株式会社コーセー リポソーム組成物、並びにそれを用いた化粧料、皮膚外用剤及びその製造方法
CN102627642A (zh) * 2012-03-19 2012-08-08 南京洵安医药科技有限公司 莫西沙星金属配合物及其制药用途
US10220095B2 (en) * 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
MX382522B (es) 2015-10-16 2025-03-13 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61130239A (ja) * 1984-11-30 1986-06-18 Dai Ichi Seiyaku Co Ltd 複合体
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
JPH0447351A (ja) * 1990-06-12 1992-02-17 Nec Corp シングルチップマイクロコンピュータ
AU705718B2 (en) * 1995-05-24 1999-05-27 Alcon Laboratories, Inc. Antibacterial compositions
WO1999055743A1 (en) * 1998-04-28 1999-11-04 Inex Pharmaceuticals Corporation Polyanionic polymers which enhance fusogenicity

Also Published As

Publication number Publication date
HK1044122A1 (en) 2002-10-11
MXPA01010977A (es) 2002-07-22
NO320629B1 (no) 2006-01-02
DK1176962T3 (da) 2004-06-14
EP1176962A2 (de) 2002-02-06
NO20015246D0 (no) 2001-10-26
IL146113A0 (en) 2002-07-25
HK1044122B (en) 2004-11-26
WO2000066126A2 (en) 2000-11-09
AU4500600A (en) 2000-11-17
AU767474B2 (en) 2003-11-13
KR100766753B1 (ko) 2007-10-17
CA2371483A1 (en) 2000-11-09
DE60008234D1 (de) 2004-03-18
ZA200108907B (en) 2002-12-24
CN1172670C (zh) 2004-10-27
ES2214269T3 (es) 2004-09-16
IL146113A (en) 2006-07-05
DE60008234T2 (de) 2004-12-30
JP2002543134A (ja) 2002-12-17
EP1176962B1 (de) 2004-02-11
KR20020011978A (ko) 2002-02-09
HUP0201644A2 (hu) 2002-12-28
WO2000066126A3 (en) 2001-04-05
NO20015246L (no) 2001-12-28
HUP0201644A3 (en) 2004-05-28
CN1351495A (zh) 2002-05-29

Similar Documents

Publication Publication Date Title
ATE259231T1 (de) Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung
AU5905400A (en) Methods and compositions for delivery and retention of active agents to lymph nodes
DE60041976D1 (de) Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
PT915898E (pt) Forma i cristalina de claritromicina
IL140710A0 (en) Pulmonary delivery of active agents
EE200300151A (et) Ravimitena kasutatavad antikolinergikumid ning meetodid nende valmistamiseks
MA26938A1 (fr) Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacterien.
AU4460900A (en) Carrier patch for the delivery of agents to the skin
BR9908273A (pt) Formulações
WO2001027099A3 (en) Bicyclic compounds composition and method for stabilizing the same
ATE305989T1 (de) Polyelektrolyt-feststoffsystem, verfahren zur herstellung desselben sowie wundverband
AU7079700A (en) Improved stable formulations of ace inhibitors, and methods for preparation thereof
WO2003051275A3 (en) Benzodiazepine derivatives, preparation thereof and use thereof
DE60021963D1 (de) Verfahren zur Herstellung von Celluloseether
EP1167354A3 (de) Racemisches Huperzin A
NO20023139D0 (no) Liposomer som inneholder en forbindelse i supermettet lösning
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
AU2420001A (en) Methods and compositions for the treatment of pain
DE50013756D1 (de) Verfahren zur herstellung von verzweigten, weitgehend ungesättigten fettalkoholpolyglycolethern
DE60237388D1 (de) Verfahren zur herstellung von zusammensetzungen mit erhöhtem gehalt von salzen pharmazeutisch aktiver rotamere
DE60034843D1 (de) Verfahren zur Herstellung von L-arginin
EA200000172A3 (ru) Способ получения стимуляторов секреции гормонов роста
WO2002038106A3 (en) Calcilytic compounds
DK1181300T3 (da) 6-O-carbamatketolidderivater

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties